A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies
Conditions: Relapsed/Refractory Advanced Solid Tumors; Relapsed/Refractory Diffuse Large B-cell Lymphoma or Mantle Cell Lymphoma; Relapsed/Refractory Myelodysplasia; Relapsed/Refractory Myelofibrosis Intervention: Drug: PRT543 Sponsor: Prelude Therapeutics Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials